Aadi Bioscience, Inc
68 articles with Aadi Bioscience, Inc
-
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
3/28/2023
Aadi Bioscience, Inc. today provided a corporate update and announced financial results for the fourth quarter and full-year 2022.
-
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
3/27/2023
Aadi Bioscience, Inc. today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors.
-
Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer
3/26/2023
Aadi Bioscience, Inc. announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL.
-
Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
3/15/2023
Aadi Bioscience, Inc. today announced that it will host a conference call and live webcast on Tuesday, March 28, 2023 at 8:30 am EDT (5:30 am PDT) to report fourth quarter and full-year 2022 financial results and provide recent corporate updates.
-
Aadi Bioscience Announces Leadership Transition
3/3/2023
Aadi Bioscience, Inc. announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company.
-
Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference
2/22/2023
Aadi Bioscience, Inc. announced today participation at the 43rd Annual Healthcare Conference being held March 6-8, 2023, in Boston, MA.
-
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
11/17/2022
Aadi Bioscience, Inc. today presented three posters on completed and ongoing clinical trials for nab-sirolimus at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place November 16-19, 2022 in Vancouver, Canada.
-
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
11/9/2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the third quarter of 2022.
-
Aadi Bioscience Announces Planned Leadership Transition - November 08, 2022
11/8/2022
Aadi Bioscience, Inc. announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, Chief Operating Officer, to President and CEO, effective as of January 1, 2023.
-
Aadi Bioscience to Present at Upcoming Investor Conferences
11/3/2022
Aadi Bioscience, Inc. today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences during November.
-
Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update
11/2/2022
Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will host a conference call and live webcast on Wednesday, November 9, 2022 at 8:30 am ET (5:30 am PT) to report third quarter 2022 financial results and provide recent corporate updates.
-
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation
10/12/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), and Aadi Bioscience, Inc. (Nasdaq: AADI), today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors.
-
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium
10/12/2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that preclinical combination data of KRAS inhibitors and nab-sirolimus will be presented during a poster session at the upcoming 34th EORTC-NCI-AACR Symposium.
-
Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform.
-
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
9/22/2022
Aadi Bioscience, Inc. announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock at a price of $12.50 per share.
-
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences
9/1/2022
Aadi Bioscience, Inc. (NASDAQ: AADI), today announced that the Company will be participating in and hosting one-on-one meetings at the following conferences during September.
-
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
8/10/2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022.
-
Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update
7/28/2022
Company to Host Conference Call and Webcast on August 10.
-
Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes
6/23/2022
Aadi Bioscience, Inc. announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of additions posted by FTSE Russell on June 3, 2022.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.